	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	C 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Total Revenue	2,696	3,211	4,185	4,653	6,591	5,816	5,950	7,673	7,939	8,005	8,508	9,620	10,728	11,516	13,980
Cost of Operating Revenue	981	1,051	1,387	1,665	1,887	2,182	2,185	2,936	2,904	2,893	3,199	3,530	3,583	3,679	4,644
Gross Profit	1,715	2,161	2,797	2,988	4,704	3,634	3,764	4,737	5,035	5,112	5,309	6,090	7,145	7,837	9,336
Gross Margin	63.6	67.3	66.8	64.2	71.4	62.5	63.3	61.7	63.4	63.9	62.4	63.3	66.6	68.0	66.8
Total Operating Expenses	2,255	2,600	3,232	3,824	4,095	4,732	5,009	6,304	6,420	6,176	6,739	7,480	8,155	8,590	10,540
Operating Profit	441	612	953	830	2,495	1,084	941	1,369	1,519	1,828	1,769	2,140	2,572	2,926	3,440
Operating Margin	16.4	19.0	22.8	17.8	37.9	18.6	15.8	17.8	19.1	22.8	20.8	22.2	24.0	25.4	24.6
Financing Income/(Expense) - Net	-16	9	-105	108	-16	17	-12	-449	-331	-306	-68	-317	-328	-232	-501
Profit before Taxes	359	579	844	940	2,343	1,088	931	562	1,187	1,526	1,226	1,847	2,352	2,673	2,872
Income Taxes	72	147	180	189	610	155	253	125	215	274	449	602	696	762	734
Profit after Tax	284	430	664	751	1,733	934	678	436	1,025	1,252	777	1,245	1,656	1,911	2,163
PAT Margin	10.5	13.4	15.9	16.1	26.3	16.1	11.4	5.7	12.9	15.6	9.1	12.9	15.4	16.6	15.5
EPS - Basic - ex Extraordinary Items	16.78	25.40	19.62	22.19	51.21	27.58	20.04	12.89	28.72	36.99	22.96	36.79	48.94	56.47	63.92
EPS - Diluted - ex Extraordinary Items	16.78	25.57	19.62	22.19	51.21	27.58	20.04	12.89	28.72	36.99	22.96	36.79	48.94	56.47	63.92
EBIT	441	612	953	830	2,495	1,084	941	1,369	1,519	1,828	1,769	2,140	2,572	2,926	3,440
EBITDA	523	694	1,040	1,020	2,733	1,377	1,349	1,983	2,170	2,486	2,431	2,842	3,368	3,721	4,558
EBITDA Margin	19.4	21.6	24.8	21.9	41.5	23.7	22.7	25.8	27.3	31.1	28.6	29.5	31.4	32.3	32.6

Balance Sheet

Abridged

Understanding Balance Sheet

Torrent Pharmaceuticals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	R 2013 Mar 31	2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	1,987	2,561	3,404	4,098	4,688	4,879	5,262	5,038	4,981	5,523	5,295	5,329	5,611	5,623	9,392
Long-Term Investments	38	0	0	1	0	0	0	65	93	68	68	71	33	45	113
Property Plant & Equipment - Net	892	1,082	1,381	1,561	2,017	2,334	2,840	3,280	3,530	3,629	3,247	3,460	3,578	3,823	5,366
Total Non-Current Assets	1,073	1,223	1,665	3,866	4,370	4,823	8,981	9,083	9,029	8,551	7,805	9,683	9,449	9,367	34,920
Total Assets	3,060	3,784	5,070	7,964	9,058	9,702	14,243	14,121	14,010	14,075	13,100	15,012	15,061	14,990	44,312
Total Current Liabilities	1,363	1,711	2,175	2,705	3,285	2,738	5,202	5,165	5,454	4,892	4,415	5,447	5,425	4,717	8,343
Long Term Debt	322	455	744	2,173	1,850	2,241	4,111	3,913	3,304	2,963	2,160	2,549	1,668	1,338	11,841
Total Non-Current Liabilities	499	651	992	2,616	2,278	2,613	4,416	4,227	3,727	3,343	2,730	3,365	2,778	2,681	18,361
Total Liabilities	1,862	2,362	3,167	5,321	5,563	5,351	9,618	9,392	9,181	8,234	7,145	8,812	8,203	7,399	26,705
Total Shareholders' Equity	1,194	1,422	1,902	2,643	3,494	4,350	4,625	4,729	4,829	5,840	5,955	6,200	6,857	7,591	8,411
Minority Interest	4	0	0	0	0	0	1	-	-	-	-	-	-	-	9,196
Total Equity	1,197	1,422	1,903	2,643	3,495	4,351	4,625	4,729	4,829	5,840	5,955	6,200	6,857	7,591	17,607
Total Liabilities & Equity	3,060	3,784	5,070	7,964	9,058	9,702	14,243	14,121	14,010	14,075	13,100	15,012	15,061	14,990	44,312

Cash Flow

Abridged

Understanding Cash Flow Statement

Torrent Pharmaceuticals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	R 2020 Mar 31	C 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	354	578	690	1,043	2,113	948	985	1,203	1,310	1,993	1,904	2,096	2,490	2,824	2,973
Working Capital - Increase/(Decrease)	144	-422	-120	-409	424	-125	-360	99	-386	-338	-352	-18	418	-481	-342
Net CF from Operating Activities	498	156	570	634	2,537	823	625	1,303	924	1,655	1,553	2,078	2,908	2,343	2,631
Capital Expenditures - Net	160	284	398	236	592	486	789	661	403	334	196	415	299	594	636
Net CF from Investing Activities	-166	-276	-388	-2,180	-844	-792	-4,713	-249	182	-455	-204	-2,428	-181	-560	-12,749
Dividends Paid - Cash - Total	137	83	267	200	840	204	265	310	719	338	677	863	1,015	1,083	1,289
Debt - LT & ST - Issuance/(Retirement) - Total	-25	139	414	1,606	-384	202	3,958	-501	-345	-956	-846	1,243	-1,393	-953	11,867
Net Cash Flow from Financing Activities	-162	51	147	1,407	-1,223	-2	3,693	-811	-1,064	-1,295	-1,523	380	-2,409	-2,036	10,578
Free Cash Flow to Equity	313	11	586	2,003	1,560	539	3,793	141	176	364	510	2,906	1,216	796	13,862
Free Operating CF net dividend	199	-220	-97	191	1,098	132	-431	330	-201	981	673	641	1,460	648	665
Free Operating CF	337	-137	170	391	1,938	336	-167	640	518	1,319	1,350	1,504	2,475	1,731	1,954

Business Segment Analysis

FY End:

Mar 26

Torrent Pharmaceuticals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Generic Formulation Business (100.0%)₹ 677.39 Cr

Revenue / Sales

Generic Formulation Business (100.0%)₹ 13,979.73 Cr

Assets

Generic Formulation Business (100.0%)₹ 44,311.96 Cr

Operating Income

Generic Formulation Business (100.0%)₹ 3,439.76 Cr

Regional Segment Analysis

FY End:

Mar 26

Torrent Pharmaceuticals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (58.4%)₹ 8,161.35 CrOther countries (13.2%)₹ 1,844.61 CrUSA (9.7%)₹ 1,362.65 CrBRAZIL (9.7%)₹ 1,362.42 CrGERMANY (8.9%)₹ 1,248.70 Cr

Historical Segment Analysis

Track how Torrent Pharmaceuticals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Generic Formulation Business	407	335	203	574	433	612	677

Frequently Asked Questions

What is the revenue of Torrent Pharmaceuticals Ltd.?

The latest trailing twelve month revenue of Torrent Pharmaceuticals Ltd. is ₹ 13,980.00 Cr, reflecting a 1-year growth of 21.40% and a 3-year CAGR of 13.27%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Torrent Pharmaceuticals Ltd.?

The latest trailing twelve month net profit (PAT) of Torrent Pharmaceuticals Ltd. is ₹ 2,163.00 Cr, with a 3-year earnings CAGR of 20.22%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Torrent Pharmaceuticals Ltd.?

The trailing twelve month EBITDA of Torrent Pharmaceuticals Ltd. is approximately ₹ 3,440.00 Cr (based on an operating margin of 24.61%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Torrent Pharmaceuticals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Torrent Pharmaceuticals Ltd. is 63.92. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Torrent Pharmaceuticals Ltd.?

The debt-to-equity ratio of Torrent Pharmaceuticals Ltd. stands at 1.79. The interest coverage ratio is 8.94x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Torrent Pharmaceuticals Ltd.?

The estimated book value per share of Torrent Pharmaceuticals Ltd. is 253.86 (derived from a P/B ratio of 18.81 and market price of ₹ 4,774.00), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Torrent Pharmaceuticals Ltd.?

The trailing twelve month operating cash flow of Torrent Pharmaceuticals Ltd. is ₹ 2,632.00 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Torrent Pharmaceuticals Ltd. report consolidated or standalone financials?

Torrent Pharmaceuticals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.